Post by
mercedesman on Nov 17, 2021 9:49pm
Great expectations
"I would also think about the OPEN LABEL structure of the phase 3B trial and the clear ability to produce rather stunning 20%+ absolute efficacy benefits when the "Golden Hour" strikes their mood." -STT
Ya gotta believe their expectation would be to produce Euphas like results, no?
I'm excited about the possibility of 20%+. Any idea what that would be on a relative benefit basis? PMX use compared to Sham in the .6 to .89 group was associated with a 29% relative risk reduction in mortality at 28 days. And that was with an approx 11% absolute benefit.
I'm not good with math so what would the 20% Absolute Benefit translate into on a relative risk reduction basis? 40% ? more ? I'd multiply by 2.71 (= 29/10.7) but then I get 54.2 and that doesn't seem right (seems too pumpy for my taste)
MM